Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on the minutes from Ascelia’s Type A meeting with the FDA and subsequent conference call.</li></ul>

Redeye comments on the minutes from Ascelia’s Type A meeting with the FDA and subsequent conference call.

<ul><li>Redeye returns with an update on Ascelia after the Q2 report, which contained few surprises.</li><li>We reiterate our fair value and the company screens "fairly priced" at the moment.</li></ul>

Redeye returns with an update on Ascelia after the Q2 report, which contained few surprises.We reiterate our fair value and the company screens "fairly priced" at the moment.

Ascelia (Q2 review): All eyes on September meeting

<ul><li>Redeye returns with an update following the CRL and additional consideration, where we lower the likelihood of approval, include an assumed rights issue, and a later deal and launch.</li><li>We cut our Fair Value, which also takes peer valuation into account, to SEK1 per share - which screens fairly valued.</li></ul>

Redeye returns with an update following the CRL and additional consideration, where we lower the likelihood of approval, include an assumed rights issue, and a later deal and launch.We cut our Fair Value, which also takes peer valuation into account, to SEK1 per share - which screens fairly valued.

<ul><li>Redeye comments on the publication of the Complete Response Letter and Ascelia's subsequent press release.</li><li>Our valuation is under review.</li></ul>

Redeye comments on the publication of the Complete Response Letter and Ascelia's subsequent press release.Our valuation is under review.

<ul><li>Redeye comments on the disappointing news that Ascelia has received a CRL from the FDA for Orviglance.</li><li>We place our valuation under review following this negative outcome and give a first comment.</li></ul>

Redeye comments on the disappointing news that Ascelia has received a CRL from the FDA for Orviglance.We place our valuation under review following this negative outcome and give a first comment.

Ascelia: Orviglance receives a CRL – our initial comment

Sweden

Ascelia Pharma AB operates as a drug development company. The Company develops medicines and drugs for the treatment of liver metastases and gastric cancer. Ascelia Pharma serves patients in Sweden.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ascelia Pharma (ACE SS)

Ascelia: Our comment on the FDA minutes

Redeye comments on the minutes from Ascelia’s Type A meeting with the FDA and subsequent conference call.

Redeye

Ascelia (Q2 review): All eyes on September meeting

Redeye returns with an update on Ascelia after the Q2 report, which contained few surprises. We reiterate our fair value and the company screens...

Redeye

Ascelia: Type A Meeting decides the path

Redeye returns with an update following the CRL and additional consideration, where we lower the likelihood of approval, include an assumed rights...

Redeye

Ascelia: Additional comment on the CRL

Redeye comments on the publication of the Complete Response Letter and Ascelia's subsequent press release. Our valuation is under review.

Redeye

Ascelia: Orviglance receives a CRL – our initial comment

Redeye comments on the disappointing news that Ascelia has received a CRL from the FDA for Orviglance. We place our valuation under review...

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)